In the Spotlight
Evista for Chemoprevention of Breast Cancer: Better Late Than Never, FDA
Gilbert L. Ross, M.D., Medical Progress Today, 9-28-07
An aphorism never truer: when discussing breast cancer, an ounce of prevention is better for public health than the cures currently available, and much cheaper. So, after a long–and–winding eight–year period of data accumulation, we should applaud the FDA for finally approving Lilly's "designer estrogen," Evista (raloxifene), for use in postmenopausal high–risk women to lower their risk of invasive breast cancer. But we should question why the FDA took this long in the first place.
Continue reading . . .
· Medical Device Recalls and the FDA Approval Process, Zuckerman, D. M., Brown, P., Nissen, S. E., Archives of Internal Medicine, 6-14-11
· Patent Reform Gets Key Support in House, Julian Pecquet, The Hill, 6-14-11
· $4.3 Billion Pledged at Vaccine Fund-Raiser, Donald G. McNeil Jr., New York Times, 6-13-2011
· Physicians Leaving Practices for health System Employment, Karen Cheung, FierceHealthcare, 6-13-11
More Headlines >>
Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.
For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at email@example.com, or via telephone at 212.599.7000.
Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at firstname.lastname@example.org, or via telephone at 212.599.7000.
If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.